Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases

REFERENCES

• UNAIDS Report on the Global AIDS Epidemic. http://www.unaids.org/globalreport/Global_report.htm. Accessed February 23,2011.
   Google Scholar
• Altman RB, Kroemer HK, McCarty CA, Ratain MJ, Roden D. Pharmacogenomics: will the promise be fulfilled? Nat Rev Genet. 2010;12: 69–73.
   PubMed Web of Science ®Google Scholar
• Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121–1122.
   PubMed Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–732.
   PubMed Web of Science ®Google Scholar
• Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46:1111–1118.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screen-ing for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–579.
   PubMed Web of Science ®Google Scholar
• The Panel on Clinical Practices for Treatment of HIV-1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 10,2011. http://www.aidsinfo.nih.gov/. Accessed February 23, 2011.
   Google Scholar
• Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391–2400.
   PubMed Web of Science ®Google Scholar
• Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15:1–5.
   PubMedGoogle Scholar
• Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenet-ics of long-term responses to antiretroviral regimens con-taining efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis. 2005;192:1931–42.
   PubMed Web of Science ®Google Scholar
• Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics. 2006;16:191–198.
   PubMed Web of Science ®Google Scholar
• Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007;81:557–566.
   PubMed Web of Science ®Google Scholar
• Ribaudo HJ, Liu H, Schwab M, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz phar-macokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis. 2010;202:717–722.
   PubMed Web of Science ®Google Scholar
• Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1"0101 and abrogated by low CD4 T-cell counts. AIDS. 2005;19:97–99.
   PubMed Web of Science ®Google Scholar
• Likanonsakul S, Rattanatham T, Feangvad S, et al. HLA-Cw"04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res Ther 2009;6:22–28.
   PubMedGoogle Scholar
• Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLA-B"3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics. 2009;19:139–146.
   PubMed Web of Science ®Google Scholar
• Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1"01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS. 2008;22:540–541.
   PubMed Web of Science ®Google Scholar
• Lubomirov R, di Lulio J, Fayet A, et al. ADME pharma-cogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics. 2010;20:217–230.
   PubMed Web of Science ®Google Scholar
• Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV pro-tease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics. 2010;20:112–120.
   PubMed Web of Science ®Google Scholar
• Arab-Alameddine M, Di lulio J, Buclin T, et al. Pharma-cogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 2009;85:485–494.
   PubMed Web of Science ®Google Scholar
• Rotger M, Bayard C, Taffe P, et al. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected indi-viduals: a longitudinal study. Circ Cardiovasc Genet. 2009;2:621–628.
   PubMed Web of Science ®Google Scholar
• Rotger M, Gsponer T, Martinez R, et al. Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. Clin Infect Dis. 2010;51:1090–1098.
   PubMed Web of Science ®Google Scholar
• Ge D, FeIlay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clear-ance. Nature. 2009;461:399–401.
   PubMed Web of Science ®Google Scholar
• Roden DM, Pulley JM, Basford MA, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008;84: 362–369.
   PubMed Web of Science ®Google Scholar
• Zucker SD, Qin X, Rouster SD, et al. Mechanism of indina-vir-induced hyperbilirubinemia. Proc Natl Acad Sc/ USA. 2001;98:12671–12676.
   PubMed Web of Science ®Google Scholar
• O'Mara, et al. Population pharmacodynamic assessment of atazanavir exposure, uridine diphosphate-glucuronosyl transferase (UGT) 1A1 genotype and safety in healthy subjects [abstract 3051]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago), Washington, DC: American Society for Microbiology; 2003.
   Google Scholar
• Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 2005;192:1381–1386.
   PubMed Web of Science ®Google Scholar
• Kohlrausch FB, de Cassia Estrela R, Barroso PF and Suarez-Kurtz G. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol. 2010;69:95–98.
   PubMed Web of Science ®Google Scholar
• Lillibridge JH, Lee CA and Pithavala YK. The role of poly-morphic CYP2C19 in the metabolism of nelfinavir mesyl-ate [abstract 3035]. Presented at XII Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists (San Francisco). Arlington, VA: American Asso-ciation of Pharmaceutical Scientists; 1998.
   Google Scholar
• Saitoh A, Series E, Capparelli E, et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007;21:2191–2199.
   PubMed Web of Science ®Google Scholar
• Chantarangsu S, Cressey TR, Mahasirimongkol S, et al. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. J Antimicrob Chemother 2009;64:1265–1273.
   PubMed Web of Science ®Google Scholar
• Mahungu T, Smith C, Turner F, et al. Cytochrome P450 2B6 516G>T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med. 2009;10:310–317.
   PubMed Web of Science ®Google Scholar
• Tarr PE, Taffe P, Bleiber G, et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis. 2005;191:1419–1426.
   PubMed Web of Science ®Google Scholar
• Foulkes AS, Wohl DA, Frank I, et al. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med. 2006;3:e52.
   PubMed Web of Science ®Google Scholar